MIDATECH PHARMA
R&D | Immunotherapy

Autoimmune Disease (MTX102)

Midacore® gold nanoparticles can be linked to antigen specific peptides, small proteins and tolerogenic cytokines, that are key mediators in autoimmune diseases such as type 1 diabetes.  MTX102 is a gold nanoparticle construct containing multiple copies of a proinsulin pancreatic beta-cell antigenic peptide that it implicated as a causal agent in some types of autoimmune diabetes.  The peptide has been clinically validated in the naked peptide form, and the enhanced Midacore® antigen specific immunotherapy (ASI) version (MTX102) has been shown to enable targeted delivery of a pancreatic beta cell antigen to antigen presenting cells in the superficial layers of the skin using microneedles. Validation of manufacture and in vitro and in vivo preclinical efficacy has been demonstrated during early development.  A First-in-Man Phase 1 clinical trial is underway to confirm safety of this innovative vaccine (MTX102) for type 1 diabetes in humans. The results from this Phase 1 study are expected in early 2019.  We anticipate that the ASI system will be less costly, more effective and more acceptable to patients in improving glycaemic control than exogenous insulin replacement.

Midatech have also been awarded a JDRF grant in 2017, in collaboration with Cardiff University, to investigate the addition of small molecule ligands to the Midacore® platform to enhance the tolerogenic response to peptide conjugated gold nanoparticles.

Immuno-oncology

MTR111 (DIPG Vaccine)

Midatech is partnering with University of California San Francisco (UCSF) to evaluate Midacore® versions of peptide cancer epitopes that are of potential value for treating DIPG.  Key preclinical data are expected in 2018 and if encouraging, MTR111 is expected to enter clinical development in 2019.

MTR116 (Glioblastoma Multiforme (GBM) Vaccine)

Several antigenic GBM peptides are under evaluation in clinical trials.  Midatech has developed next generation Midacore® nanoparticle complexes that combine similar peptides.  These have the potential to deliver an enhanced immunogenic response and improved efficacy.   The program is currently in preclinical development and if data are encouraging, the selected candidate is expected to enter clinical development in 2019.

R&D
R&D
Immunotherapy

Autoimmune Disease (MTX102)

Midacore® gold nanoparticles can be linked to antigen specific peptides, small proteins and tolerogenic cytokines, that are key mediators in autoimmune diseases such as type 1 diabetes.  MTX102 is a gold nanoparticle construct containing multiple copies of a proinsulin pancreatic beta-cell antigenic peptide that it implicated as a causal agent in some types of autoimmune diabetes.  The peptide has been clinically validated in the naked peptide form, and the enhanced Midacore® antigen specific immunotherapy (ASI) version (MTX102) has been shown to enable targeted delivery of a pancreatic beta cell antigen to antigen presenting cells in the superficial layers of the skin using microneedles. Validation of manufacture and in vitro and in vivo preclinical efficacy has been demonstrated during early development.  A First-in-Man Phase 1 clinical trial is underway to confirm safety of this innovative vaccine (MTX102) for type 1 diabetes in humans. The results from this Phase 1 study are expected in early 2019.  We anticipate that the ASI system will be less costly, more effective and more acceptable to patients in improving glycaemic control than exogenous insulin replacement.

Midatech have also been awarded a JDRF grant in 2017, in collaboration with Cardiff University, to investigate the addition of small molecule ligands to the Midacore® platform to enhance the tolerogenic response to peptide conjugated gold nanoparticles.

Immuno-oncology

MTR111 (DIPG Vaccine)

Midatech is partnering with University of California San Francisco (UCSF) to evaluate Midacore® versions of peptide cancer epitopes that are of potential value for treating DIPG.  Key preclinical data are expected in 2018 and if encouraging, MTR111 is expected to enter clinical development in 2019.

MTR116 (Glioblastoma Multiforme (GBM) Vaccine)

Several antigenic GBM peptides are under evaluation in clinical trials.  Midatech has developed next generation Midacore® nanoparticle complexes that combine similar peptides.  These have the potential to deliver an enhanced immunogenic response and improved efficacy.   The program is currently in preclinical development and if data are encouraging, the selected candidate is expected to enter clinical development in 2019.

© Copyright 2018 Midatech Pharma PLC